Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., … Schilsky, R. L. (2018). Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In Journal of Clinical Oncology (Vol. 36, pp. 2532–2532). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.2532

Al Baghdadi, Tareq, Susan Halabi, Elizabeth Garrett-Mayer, Pam K. Mangat, Eugene R. Ahn, Vaibhav Sahai, Ricardo H. Alvarez, et al. “Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In Journal of Clinical Oncology, 36:2532–2532. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2532.

Al Baghdadi T, Halabi S, Garrett-Mayer E, Mangat PK, Ahn ER, Sahai V, et al. Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2532–2532.

Al Baghdadi, Tareq, et al. “Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 2532–2532. Crossref, doi:10.1200/jco.2018.36.15_suppl.2532.

Al Baghdadi T, Halabi S, Garrett-Mayer E, Mangat PK, Ahn ER, Sahai V, Alvarez RH, Kim ES, Yost KJ, Guo K, Rygiel AL, Antonelli KR, Butler NL, Bruinooge SS, Schilsky RL. Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2532–2532.